Kazusamycin A | CAS#92090-94-3 | antitumor antibiotic

MedKoo Cat#: 558170 | Name: Kazusamycin A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Kazusamycin A is a new antitumor antibiotic. It has a structure characteristic of an unsaturated, branched-chain fatty acid with a terminal delta-lactone ring.

Chemical Structure

Kazusamycin A

CAS#92090-94-3

Theoretical Analysis

MedKoo Cat#: 558170

Name: Kazusamycin A

CAS#: 92090-94-3

Chemical Formula: C33H48O7

Exact Mass: 556.3400

Molecular Weight: 556.74

Elemental Analysis: C, 71.19; H, 8.69; O, 20.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Antibiotic 81-484; Antibiotic CL1957B; Kazusamycin A; PD 114721;

IUPAC/Chemical Name

2,10,12,16,18-Nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-8-oxo-

InChi Key

KZMHNEBMQDBQND-MRBODPGGSA-N

InChi Code

InChI=1S/C33H48O7/c1-8-27(13-14-29-24(5)12-15-31(37)40-29)17-21(2)10-9-11-22(3)18-28(20-34)33(39)26(7)32(38)25(6)16-23(4)19-30(35)36/h9,11-15,17-19,21,24-26,28-29,32,34,38H,8,10,16,20H2,1-7H3,(H,35,36)/b11-9+,14-13+,22-18+,23-19+,27-17+

SMILES Code

O=C(O)/C=C(C)/CC(C)C(O)C(C)C(C(CO)/C=C(C)/C=C/CC(C)/C=C(CC)/C=C/C1C(C)C=CC(O1)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 556.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ando R, Amano Y, Nakamura H, Arai N, Kuwajima I. Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3315-8. Epub 2006 Apr 17. PubMed PMID: 16617017. 2: Komiyama K, Okada K, Oka H, Tomisaka S, Miyano T, Funayama S, Umezawa I. Structural study of a new antitumor antibiotic, kazusamycin. J Antibiot (Tokyo). 1985 Feb;38(2):220-9. PubMed PMID: 3922934. 3: Umezawa I, Komiyama K, Oka H, Okada K, Tomisaka S, Miyano T, Takano S. A new antitumor antibiotic, kazusamycin. J Antibiot (Tokyo). 1984 Jul;37(7):706-11. PubMed PMID: 6432763. 4: Arai N, Chikaraishi N, Omura S, Kuwajima I. First total synthesis of the antitumor compound (-)-kazusamycin A and absolute structure determination. Org Lett. 2004 Aug 19;6(17):2845-8. PubMed PMID: 15330629. 5: Sawamura M. [Growth inhibitory effect of a new anticancer antibiotics, kazusamycin A, on human transitional cancer cell lines in vitro]. Nihon Hinyokika Gakkai Zasshi. 1992 May;83(5):627-35. Japanese. PubMed PMID: 1495200. 6: Komiyama K, Okada K, Hirokawa Y, Masuda K, Tomisaka S, Umezawa I. Antitumor activity of a new antibiotic, kazusamycin. J Antibiot (Tokyo). 1985 Feb;38(2):224-9. PubMed PMID: 3922935. 7: Umezawa I, Komiyama K. [Studies on the new antibiotic kazusamycin and related substances]. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):858-64. Japanese. PubMed PMID: 3105461. 8: Umezawa I. [Biological activities of a new antitumor antibiotics]. Gan To Kagaku Ryoho. 1984 Dec;11(12 Pt 2):2674-80. Japanese. PubMed PMID: 6439122. 9: Tunac JB, Graham BD, Dobson WE, Lenzini MD. Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity. J Antibiot (Tokyo). 1985 Apr;38(4):460-5. PubMed PMID: 3924872. 10: Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 1986;16(2):95-101. PubMed PMID: 3081269. 11: Yoshida E, Nishimuta Y, Naito K, Watanabe Y, Tomisaka S, Okura A, Komiyama K, Umezawa I. The effect of kazusamycin on the growth of murine solid tumors and their spontaneous metastasis. J Antibiot (Tokyo). 1987 Mar;40(3):391-3. PubMed PMID: 3106290.